CRISPR Therapeutics
NEWS
This year’s top 30 large and small companies operate in some of the Life Sciences’ hottest spaces – precision medicine, vaccines, gene editing, genomics and oncology.
Clade Therapeutics will use its funds to further its research and development on cancer treatments, while GRO Biosciences will focus on chronic diseases.
It was yet another busy week for clinical trial announcements. Take a look.
CRISPR Therapeutics provided updated data from its ongoing Phase I CARBON trial of CTX110, its allogeneic “off-the-shelf” CAR-T therapy for CD19+ B-cell cancers.
With this milestone, the field is now wide open for the next in vivo CRISPR success, and Editas is hoping that it will be in the ocular disease space.
The company is eager to diversify, putting Phase II clinical trials in sickle-cell disease, beta-thalassemia, kidney diseases, and pain management.
Jennifer Doudna is best known for discovering CRISPR/Cas9 gene editing with Emmanuelle Charpentier, and both winning the Nobel Prize in Chemistry in 2020.
Interim results from the Phase I study presented at the Peripheral Nerve Society Annual Meeting demonstrated that the investigational therapy, NTLA-2001, greatly reduced the disease-causing protein after a single infusion.
Per the agreement, CRISPR will lead the research and development of the Friedreich’s ataxia program, while Capsida will shepherd the R&D for the ALS effort.
JOBS
IN THE PRESS